bimatoprost and Inflammation

Pigmentary disorders are common and can be very distressing to patients. There is a need for better, standardized therapies. The authors review the most recent data for topical, systemic, light, and laser treatments for vitiligo, melasma, and postinflammatory hyperpigmentation. There is a paucity of large-scale, well-designed, randomized, controlled trials for these treatments. Treatment options are often drawn from smaller trials and case series. The treatments described in this article are promising candidates for larger follow-up studies.

Topics: alpha-MSH; Antifibrinolytic Agents; Bimatoprost; Dermatologic Agents; Humans; Hydroquinones; Inflammation; Janus Kinase Inhibitors; Keratinocytes; Lasers, Solid-State; Low-Level Light Therapy; Melanocytes; Melanosis; Pigmentation Disorders; Skin Lightening Preparations; Sunscreening Agents; Tranexamic Acid; Vitiligo